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ABSTRACT
Objective: To evaluate in a longitudinal study the influence of airway hyperresponsiveness (AHR) on
lung function in patients with primary Sj€ogren’s syndrome (pSS).
Methods: Lung function was studied over an eight-year period in 15 patients who fulfilled the
Copenhagen criteria for primary Sj€ogren’s syndrome and who were covered in our earlier published
study on AHR in patients with Sj€ogren’s syndrome. Standard spirometry and measurements of lung
volumes, diffusing capacity (DLCO), and AHR to methacholine were performed.
Results: A significant decline over time was found in total lung capacity (TLC), vital capacity (VC),
forced vital capacity (FVC), functional residual capacity (FRC), and expiratory midflows (FEF50). A sign of
small airway obstruction (decrease in FEF50) at entry correlated with VC at follow-up (r¼ .8,P< .003),
and the individual change in FEF50 during the observation period correlated with the individual change
in VC (r¼ .6, P< .05). Six patients had increased AHR, and three of them had decreased DLCO. Six of
the patients progressively reduced DLCO over time, and five of them had spirometric signs of
increased small airway obstruction.
Conclusions: During this eight-year follow-up we observed that one-third of the patients with pSS
developed a significant reduction in lung function. Our findings suggest that small airways obstruction
and AHR are associated with reduction of VC and development of impaired DLCO as a sign of intersti-
tial lung disease in this group of patients.
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Introduction
Primary Sj€ogren’s syndrome (pSS) is a chronic autoimmune
inflammatory disease that mainly affects exocrine glands of
the mucous membranes (1). In addition, a wide spectrum of
extraglandular symptoms may occur, e.g. from the respiratory
system (2–6). A significant number of patients with pSS have
symptoms of xerotracheitis, characterized by a chronic, dry,
non-productive cough and dyspnoea. These symptoms have
been attributed to dryness in the large airways caused by
dysfunction in the tracheal glands due to lymphocyte infiltra-
tion (7).
These xerotracheitis symptoms are similar to the symp-
toms of airway hyperresponsiveness (AHR). In fact, previous
studies have demonstrated that the majority of patients with
pSS suffer from hyperresponsive airways (8,9). Furthermore,
airflow obstruction has been reported in up to 12% of this
group of patients (10). It is important to distinguish between
bronchial asthma and respiratory symptoms due to pSS, as
the Sj€ogren’s patients may run the risk of developing
interstitial pneumonitis and small airway disease, with irre-
versible lung dysfunction as a possible end result (4).
Few longitudinal studies have been undertaken concern-
ing lung function in patients with pSS (4,11,12), and none of
these studies have focused on AHR. Therefore, we have
studied whether signs of peripheral or central airflow limita-
tion and AHR are related to changes in lung function over
time in this eight-year follow-up study of a group of patients
with Sj€ogren’s syndrome.
Patients and methods
We have previously reported AHR in a group of patients with
pSS (8). Now, eight years later, we have been able to re-
evaluate 15 of the 21 previously studied patients. Of the six
patients that did not participate at follow-up study, three
died, two of myocardial infarction and one of drug intoxica-
tion; two were unable to participate for geographical reasons;
and one was classified as having systemic lupus
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erythematosus. Thus, 14 women and 1 man, with a mean
age of 60 years (range 46–78) at follow-up, were included in
this study. Their disease duration at baseline was 9–15 years
(mean 13), with the diagnosis based on the Copenhagen cri-
teria as in the previous study (13). However, all patients who
participated at follow-up fulfilled also the classification crite-
ria from 2002 (14).
Four out of 15 patients (26%) had glandular symptoms
only, whereas 11 patients (73%) had extraglandular manifes-
tations: Raynaud’s phenomenon (n¼ 9), non-erosive arthritis
(n¼ 5), sun sensitivity, pancreatic insufficiency, Waldenstr€om’s
macroglobulinemia, and one patient had developed non-
Hodgkin’s lymphoma. Eleven patients (73%) had pulmonary
symptoms: dry cough (n¼ 7), asthma-like symptoms (n¼ 2),
and exertional dyspnoea (n¼ 3). All but one were non-smok-
ers, and none had a history of allergy disorders. Ten patients
had a positive ANA, and five had SSA or SSB.
At baseline six patients were treated with glucocorticoids
(mean dose: prednisolone 5mg/day), and three of them were
also treated with azathioprine and two with chloroquine. At
the follow-up an additional patient was treated with gluco-
corticoids in combination with chloroquine. None of the sub-
jects was medicated with inhaled corticosteroids.
The study was conducted in accordance with the
Declaration of Helsinki and was approved by the Ethics
Committee at the Medical Faculty at Uppsala University.
Informed consent was obtained prior to the study.
Lung function measurements
All subjects underwent lung function measurements accord-
ing to American Thoracic Society (ATS) standards (15), which
included measurements of total lung capacity (TLC), func-
tional residual capacity (FRC), and residual volume (RV). Vital
capacity (VC), forced vital capacity (FVC), forced expiratory
volume in 1 second (FEV1), flow volume registrations with
maximum expiratory flow (MEF), and flows measured at 50%
(FEF50) and 25% (FEF25) of FVC were measured with a
Masterlab body plethysmograph, and diffusion capacity for
CO (DLCO) was measured using the Masterlab Transfer test
(Eric Jaeger AB, W€urtsburg, Germany). Lung function values
are presented as a percentage of reference values according
to gender, age, and body size (16,17), and values less than
80% of predicted value were considered below normal
values.
Methacholine challenges
The methacholine test was modified from Hargreave’s
method (18). A hand-held DeVilbiss 646 nebulizer was used.
After an initial test with saline, the patients were tested with
double dilutions of methacholine, at 3-min intervals, starting
with 1.2mg/mL up to a maximum dose of 20mg/mL. The
subject inhaled for 2min, actuating the nebulizer during
each inhalation. The nebulizer was weighed before and after
each concentration, and the consumed dose was calculated.
The inhalation was discontinued when there was a fall in the
FEV1 of 20% or more below the lowest post-saline value.
Test results were expressed as the provocation dose that
caused a fall in FEV1 of 20% (PD20). Degree of AHR was div-
ided into categories based on the PD20 value: severe
(<0.125mg methacholine), moderate (0.125–1.29), mild
(1.3–5.0), and slight (5.1–9.0).
Thirteen of 15 patients underwent the methacholine chal-
lenge test; one had a FEV1 of less than 1.0 L/min, and the
other was not able to participate in this part of the study.
Both these patients demonstrated AHR at baseline.
In addition to PD20, we calculated the least-squares slope
for methacholine from the regression equation for the per-
centage decline in FEV1 on a cumulative dose of methacho-
line using all the measured points (18).
Statistics
The paired t test was used to assess changes in lung function
and airway responsiveness over time. In comparisons within
a group, the Spearman rank correlation test was used. All cal-
culations were done in StatView for Macintosh. A P value of
<.05 was regarded as statistically significant.
Results
The individual data on FEF50, DLCO, and the response to
methacholine (PD20) at baseline and at follow-up are pre-
sented in Table 1. The results for the whole group illustrate
significant decreases in several lung volumes: TLC, VC, FVC,
and FRC (Table 2). The patients also had a decrease (P< .05)
in peripheral airflow (FEF50), whereas the measurements of
central airway obstruction (MEF) did not change during the
study period.
When evaluating the airway obstruction over time, we
found that FEF50 at baseline was correlated with VC at fol-
low-up (r¼ .8, P< .003), and there was also an association
between the FEF50 at baseline and the change (D) in VC over
time (Figure 1). The individual change in FEF50 during the
observation period correlated with the individual change in
VC (r¼ .6, P< .05) (Figure 2).
Table 1. Results of FEF50, DLCO, and methacholine challenge test at baseline
and follow-up in 15 patients with primary Sj€ogren’s syndrome.
FEF50 DLCO Methacholine PD20
Case no. Baseline Follow-up Baseline Follow-up Baseline Follow-up
1 148 130 75 74 1.80 10
2 57 56 85 97 3.20 9.40
3 36 46 86 92 0.40 0.24
4 114 160 108 80 10 10
5 143 140 129 130 10 10
6 102 109 54 62 10 10
7 120 53 74 64 0.14 0.09
8 74 63 74 76 10 10
9 78 33 68 65 0.76 0.14
10 74 59 74 85 6.60 2.50
11 66 75 82 93 10 10
12 70 60 114 96 10 2.51
13 10 5 53 43 0.62 –
14 99 66 78 83 0.4 –
15 64 52 66 72 0.5 0.15
DLCO¼ diffusion capacity for CO (% of predicted); FEF50 ¼ expiratory flow
measured at 50% (% of predicted); PD20 ¼ provocation dose which causes a
decline in FEV1 of 20%.
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Seven of 13 (54%) patients with pSS were hyperresponsive
to methacholine at baseline, while 6 (46%) were hyperres-
ponsive at follow-up. In the patients with AHR at follow-up,
the decrease in DLCO was related to the dose–response
slope for methacholine (r¼ .9, P< .05). Six (46%) patients had
increased AHR over time, and three of them had a reduction
in DLCO. Two patients who were AHR-positive to methacho-
line in the previous evaluation did not demonstrate increased
responsiveness to methacholine at follow-up. One of these
two patients received no medical treatment, whereas the
other started treatment with glucocorticosteroids and
hydroxychloroquine during the study period. One patient
developed AHR during the study period.
The DLCO did not decline in the group during the study
period, but three patients who had decreased DLCO at base-
line and had AHR progressed in terms of DLCO impairment.
Individual changes in DLCO correlated with individual
changes in VC (r¼ .6, P< .05) (Figure 3). Moreover, we
observed that five of six patients whose DLCO decreased
progressively during the period also had progression of
peripheral airflow limitation. DLCO corrected for alveolar
volume did not change, so the decrease in DLCO could not
be explained by decreased alveolar volume.
The pulmonary compliance (Cst) was significantly lower at
follow-up compared to baseline (P< .05).
Discussion
In the present eight-year follow-up study of patients with pri-
mary Sj€ogren’s syndrome (pSS), signs of increased airflow
limitation were found during the observation period.
Furthermore, the degree of FEF50 at entry and during the
observation period was significantly related to the decrease
in VC over time. These findings suggest that small airway dis-
ease may be an important pathophysiological mechanism in
lung involvement in patients with pSS.
The few longitudinal studies which have examined the
progression of lung involvement in pSS have shown a min-
imal deterioration in respiratory function over time (11,12).
However, a reduction in the end-expiratory flow in pSS may
not always be a permanent sign, but may vary over time.
Evidence of obstructive lung disease has been demonstrated
by spirometry findings in 20%–50% of patients with pSS
(3,10), and HRCT studies have reported bronchiolectasis and
bronchiolar and bronchial thickening (19).
AHR is a characteristic finding in bronchial asthma and
has been related to bronchial inflammation and oedema of
the airway walls (20). Inhaled glucocorticoids decrease AHR
in bronchial asthma (21), but seem to have little significant
effect on AHR in pSS (22), a finding that further supports the
conclusion that there are differences in underlying mecha-
nisms for bronchoconstriction in these diseases. Furthermore,
it has been demonstrated using different provocation agents
that patients with pSS display different bronchial responsive-
ness profiles compared to patients with asthma who often
show positive response to more than one type of provoca-
tion, while patients with pSS more often are only positive to
methacholine provocations (23). It is possible that the AHR in
Table 2. Comparison of lung function tests in patients with primary Sj€ogren’s
syndrome, values as a percentage of predicted values according to actual age
and body size at baseline and at the eight-year follow-up (mean ± SD).
Baseline Follow-up P
TLC 105 ± 20 99 ± 19 <.05
VC 98 ± 26 92 ± 27 <.001
FVC 95 ± 26 89 ± 27 <.05
FRC 121 ± 26 104 ± 23 <.005
FEV1 93 ± 30 90 ± 31 ns
FEV1/VC 95 ± 17 95 ± 18 ns
FEF50 84 ± 38 71 ± 37 <.05
FEF25 73 ± 32 68 ± 35 ns
MEF 98 ± 32 99 ± 40 ns
RV 129 ± 40 127 ± 38 ns
DLCO 82 ± 21 81 ± 20 ns
Cst 135 ± 53 120 ± 48 <.05
Cst¼ static compliance; DLCO¼ diffusion capacity for CO; FEF25 ¼ expiratory
flows measured at 25%; FEF50 ¼ expiratory flows measured at 50%; FEV% ¼
forced expiratory volume in 1 second as a percentage of VC; FEV1 ¼ forced
expiratory volume in 1 second; FRC¼ functional residual capacity; FVC¼ forced
vital capacity; MEF¼maximum expiratory flow; TLC¼ total lung capacity;
VC¼ vital capacity.
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Figure 1. Linear correlation between individual percentage change (D) in VC at follow-up and FEF50 at baseline in 15 patients with primary Sj€ogren’s syndrome.
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pSS may be attributed to an inflammatory process located in
the smaller airways. In our study the airway hyperresponsive-
ness in patients with pSS was associated with a decline in
DLCO, a finding which favours the hypothesis that inflamma-
tion in the small airways may underlie AHR. The dryness of
the bronchial mucosa in pSS may also make the epithelium
more vulnerable to damage and probably induces a hyperos-
molar stage, thereby predisposing to airway remodelling and
AHR. Increased concentration of nitric oxide in the expired
air of patients with pSS further provides evidence of a
chronic inflammatory process in the airway epithelium in
patients with pSS (24).
The clinical significance of decrease in pulmonary compli-
ance in the present study is unknown. However, increased
age of the study subjects at follow-up may possibly play a
role. In contrast, increased pulmonary compliance has been
associated with pulmonary fibrosis, which we did not see in
our study group.
Airway disease in pSS appears to be produced both by
glandular and non-glandular pathology. The main histological
lesion in Sj€ogren’s syndrome consists of focal lymphocytic
infiltrates of exocrine glands (25). This may result in dysfunc-
tion of the airway glands, which may give rise to dry and irri-
tating cough – the xerotracheitis symptoms. Extraglandular
lymphocytic infiltration of the respiratory system has also
been reported in pSS. Endobronchial biopsies have detected
follicular lymphocytic bronchiolitis (5,26,27), while bronchoal-
veolar lavage (BAL) studies reported subclinical alveolitis
(28,29), characterized also by lymphocytes. In another study
an increased number of alveolar neutrophils were associated
with a reduction in DLCO, and abnormal findings on chest
HRCTs were found (30). However, our previous study did not
show an increased number of inflammatory cells or pro-
inflammatory cytokines in the BAL fluid from patients with
pSS compared to healthy controls (31). Controversial BAL
findings have therefore been reported in pSS. However, sev-
eral investigators have questioned the meaning of BAL fluid
lymphocytosis, as it may not always represent alveolitis but
rather reflect bronchial lymphocytic infiltration (7).
Our study has several limitations. Firstly, it is a small study,
and although these patients have been reported previously,
this group is of interest in context of follow-up. Secondly,
results from HRCT would have strengthened our results.
Furthermore, our patient group is initially a consecutive ser-
ies of patients from a specialist clinic. However, we were not
able totally to control the care of the patients. We used
FEF50 as an indicator of small airway obstruction, but FEF25–75
might have been more suitable. In spite of these limitations,
the result of our study is of interest for those clinicians who
are caring for patients with pSS who frequently have pul-
monary symptoms.
In summary, the present study further supports that
patients with pSS may develop AHR and signs of small air-
ways disease. Spirometry, bronchial challenge tests, and
DLCO measurements may be of value to identify patients at
risk of developing lung disease associated with Sj€ogren’s syn-
drome. Further studies are needed on this issue.
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